Presenters: PD Dr. Arno Kromminga, SVP & Chief Scientific Officer at BioAgilytix and Dr. Daniel Worms, Associate Principal Investigator at BioAgilytix
Host: GE Healthcare
The assessment of unwanted immunogenicity is a key parameter in the development process of biological protein drugs. In this webinar, BioAgilytix’s experts Dr. Arno Kromminga and Dr. Daniel Worms discuss aspects of when and how to use the Biacore™ T200 SPR System to obtain a deeper understanding of unwanted immunogenicity. Learn more about the Biacore™ T200 system in this blog.
Services
Platforms
